ENTRY       D11094                      Drug
NAME        Lanadelumab (USAN);
            Lanadelumab (genetical recombination) (JAN);
            Lanadelumab-flyo;
            Takhzyro (TN)
PRODUCT     TAKHZYRO (Takeda Pharmaceuticals America)
FORMULA     C6468H10016N1728O2012S48
EXACT_MASS  145624.115
MOL_WEIGHT  145714.225
SEQUENCE    (Heavy chain)
            EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYIMMWVRQA PGKGLEWVSG IYSSGGITVY
            ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR IGVPRRDEFD IWGQGTMVTV
            SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
            YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
            RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G
            (Light chain)
            DIQMTQSPST LSASVGDRVT ITCRASQSIS SWLAWYQQKP GKAPKLLIYK ASTLESGVPS
            RFSGSGSGTE FTLTISSLQP DDFATYYCQQ YNTYWTFGQG TKVEIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H149-H205, H225-L213, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'149-H'205, H'225-L'213, H'266-H'326, H'372-H'430, L23-L88, L133-L193, L'23-L'88, L'133-L'193)
  TYPE      Peptide
REMARK      Therapeutic category: 4490
            ATC code: B06AC05
            Product: D11094<JP/US>
EFFICACY    Immunomodulator, Plasma kallikrein inhibitor
  DISEASE   Hereditary angioedema [DS:H01006]
  TYPE      Monoclonal antibody
COMMENT     Prevention of angioedema in patients with hereditary angioedema
TARGET      KLKB1 [HSA:3818] [KO:K01324]
  PATHWAY   hsa04610(3818)  Complement and coagulation cascades
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B06 OTHER HEMATOLOGICAL AGENTS
               B06A OTHER HEMATOLOGICAL AGENTS
                B06AC Drugs used in hereditary angioedema
                 B06AC05 Lanadelumab
                  D11094  Lanadelumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Angioedema Agents
               Kallikrein Inhibitors
                Lanadelumab
                 D11094  Lanadelumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              44  Allergic agents
               449  Miscellaneous
                4490  Miscellaneous
                 D11094  Lanadelumab (USAN); Lanadelumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                KLKB1
                 D11094  Lanadelumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11094
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11094
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11094
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11094
DBLINKS     CAS: 1426055-14-2
            PubChem: 376219019
///
